<DOC>
	<DOCNO>NCT01610245</DOCNO>
	<brief_summary>This study global multicenter randomize factorial double-blind , placebo-controlled trial design evaluate ( ) efficacy safety nitazoxanide 600 mg administer orally twice daily five day compare placebo treatment acute uncomplicated influenza ( ii ) efficacy safety combination therapy nitazoxanide 600 mg plus Oseltamivir 75 mg co-administered orally twice daily five day compare nitazoxanide monotherapy ( 600 mg b.i.d . 5 day ) Oseltamivir monotherapy ( 75 mg b.i.d . 5 day ) treatment acute uncomplicated influenza .</brief_summary>
	<brief_title>Safety Efficacy Study Nitazoxanide Treatment Acute Uncomplicated Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>1 . Age 13 65 year 2 . Presence clinical sign and/or symptom consistent acute illness compatible influenza infection ( follow require ) : 1. oral temperature ≥100.4 °F ≥38 °C ( obtain office selfmeasured within 12 hour prior screen selfmeasured , subject must also take antipyretic within 4 hour prior screen ) AND 2. least one follow respiratory symptom ( cough , sore throat , nasal obstruction ) consider patient moderate severe ( great mild severity ) AND 3. one follow constitutional symptom ( fatigue , headache , myalgia , feverishness ) consider patient moderate severe ( great mild severity ) . 3 . Confirmation influenza A B infection local community one following mean : 1. institution 's local laboratory , 2. local public health system , 3. national public health system , 4. laboratory recognize national multinational influenza surveillance scheme . 4 . Onset illness 48 hour enrollment trial . Note : Time onset illness define either early : 1. time temperature first measure elevate , OR 2. time subject experienced presence least one respiratory symptom AND presence least one constitutional symptom . 5 . Willing able provide write informed consent ( include assent legal guardian 18 year age ) comply requirement protocol , include completion patient diary . 1 . Severity illness requiring anticipate require inhospital care subject define high risk complication influenza infection accord Infectious Diseases Society America ( IDSA ) guideline seasonal influenza adult child ( Committee Infectious Diseases ( CID ) 2009:48 ) current Centers Disease Control Prevention ( CDC ) criterion . Current criterion person 1365 year age risk influenza complication include ( list review update required prior initiation study least monthly study ) : 1 . Persons asthma chronic pulmonary disease , cystic fibrosis child chronic obstructive pulmonary disease adult . 2 . Persons hemodynamically significant cardiac disease . 3 . Persons immunosuppressive disorder receive immunosuppressive therapy . 4 . HIVinfected person . 5 . Persons sickle cell anemia hemoglobinopathy . 6 . Persons diseases require longterm aspirin therapy , rheumatoid arthritis Kawasaki disease . 7 . Persons chronic renal dysfunction . 8 . Persons liver disorder . 9 . Persons cancer . 10 . Persons chronic metabolic disease , diabetes mellitus , inherit metabolic disorder mitochondrial disorder . 11 . Persons neuromuscular disorder , seizure disorder cognitive dysfunction may compromise handle respiratory secretion . 12 . Residents age nursing home longterm care institution . 13 . Persons morbidly obese ( Body Mass Index ≥40 ) 14 . American Indians ( seem high risk complication last flu season ) 15 . Alaskan native ( seem high risk complication last flu season ) 2 . Females childbearing potential either pregnant , breastfeed sexually active without use birth control . Female patient childbearing potential sexually active must negative baseline pregnancy test must agree continue acceptable method birth control duration study 1 month posttreatment . A double barrier method , oral birth control pill administer least 2 monthly cycle prior study drug administration , intrauterine device ( IUD ) , medroxyprogesterone acetate administer intramuscularly minimum one month prior study drug administration acceptable method birth control inclusion study . Female subject consider childbearing potential unless postmenopausal ( absence menstrual bleeding 1 year 6 month laboratory confirmation hormonal status ) , hysterectomy , bilateral tubular ligation bilateral ovariectomy . 3 . Vaccination seasonal influenza i. August 1 , 2012 case subject enrol 2012/2013 flu season United States , ii . February 1 , 2013 case subject enrol 2013 flu season Australia New Zealand , iii . August 1 , 2013 case subject enrol 2013/2014 flu season United States , Canada , Europe , country Northern Hemisphere , iv . February 1 , 2014 case subject enrol 2014 flu season Australia New Zealand , v. August 1 , 2014 case subject enrol 2014/2015 flu season United States , Canada , Europe , country Northern Hemisphere . 4 . Receipt dose nitazoxanide , oseltamivir , zanamivir , amantadine , rimantadine within 30 day prior screen . 5 . Prior treatment investigational drug therapy within 30 day prior screen . 6 . Subjects active respiratory allergy subject expect require antiallergy medication study period respiratory allergy . 7 . Known sensitivity Nitazoxanide excipients comprise Nitazoxanide tablet . 8 . Known sensitivity Oseltamivir excipients comprise Oseltamivir capsule . 9 . Subjects unable take oral medication . 10 . Subject chronic kidney liver disease ( include Hepatitis A , B C ) know impaired hepatic and/or renal function . 11 . Presence preexist chronic infection undergo require medical therapy . 12 . Presence preexist illness , opinion investigator , would place subject unreasonably increase risk participation study . 13 . Subjects , judgment investigator , unlikely comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Influenza</keyword>
</DOC>